Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes

Nancy Yoon, Amale Lteif, KyungAh Han, Kieren Mather

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Endothelin contributes to abnormalities in peripheral blood vessel function of subjects with obesity, with or without concurrent type 2 diabetes mellitus, but it is unknown if endothelin contributes specifically to obesity and diabetes-associated changes in blood pressure. We evaluated the effect of systemic endothelin antagonism on peripheral and central hemodynamics and peripheral vascular tone in lean, obese, and type 2 diabetic subjects without overt hypertension by cuff plethysmography. We measured the effects of acute systemic infusions of BQ123 (an antagonist of type A endothelin receptors) in seven lean (body mass index [BMI] 22.7 ± 3.2 kg/m2), seven obese (BMI 35.8 ± 4.6), and six diabetic subjects (BMI 38.2 ± 5.0, glycosylated hemoglobin 8.1 ± 2.2%). BQ123 was infused via antecubital vein sequentially at infusion rates from 0.1 to 1.0 μmol/min. Diastolic blood pressure was significantly lower than baseline across this dose range, but without a clear dose dependence and without differences in the dose response across groups. Obese and diabetic subjects exhibited progressive dilation of peripheral blood vessels (P ≤ .01), with 0.03 and 1.0 μmol/min BQ123 (P = .03 comparing integrated response across groups). No significant changes were observed in systolic blood pressure, cardiac index, or stroke index. These observations confirm the relevance of endothelin in the abnormal regulation of peripheral vascular tone in obesity and diabetes, but they argue against a specific effect of endothelin in diabetes- and obesity-associated blood pressure elevations.

Original languageEnglish
Pages (from-to)182-191
Number of pages10
JournalJournal of the American Society of Hypertension
Volume2
Issue number3
DOIs
StatePublished - May 2008

Fingerprint

Endothelins
Blood Vessels
Obesity
Blood Pressure
Body Mass Index
Plethysmography
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Dilatation
Veins
Hemodynamics
Stroke
Hypertension
cyclo(Trp-Asp-Pro-Val-Leu)

Keywords

  • blood pressure
  • diabetes
  • Endothelin
  • insulin resistance
  • obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

@article{4b43c7babf2148679b428c0b15d8e9c1,
title = "Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes",
abstract = "Endothelin contributes to abnormalities in peripheral blood vessel function of subjects with obesity, with or without concurrent type 2 diabetes mellitus, but it is unknown if endothelin contributes specifically to obesity and diabetes-associated changes in blood pressure. We evaluated the effect of systemic endothelin antagonism on peripheral and central hemodynamics and peripheral vascular tone in lean, obese, and type 2 diabetic subjects without overt hypertension by cuff plethysmography. We measured the effects of acute systemic infusions of BQ123 (an antagonist of type A endothelin receptors) in seven lean (body mass index [BMI] 22.7 ± 3.2 kg/m2), seven obese (BMI 35.8 ± 4.6), and six diabetic subjects (BMI 38.2 ± 5.0, glycosylated hemoglobin 8.1 ± 2.2{\%}). BQ123 was infused via antecubital vein sequentially at infusion rates from 0.1 to 1.0 μmol/min. Diastolic blood pressure was significantly lower than baseline across this dose range, but without a clear dose dependence and without differences in the dose response across groups. Obese and diabetic subjects exhibited progressive dilation of peripheral blood vessels (P ≤ .01), with 0.03 and 1.0 μmol/min BQ123 (P = .03 comparing integrated response across groups). No significant changes were observed in systolic blood pressure, cardiac index, or stroke index. These observations confirm the relevance of endothelin in the abnormal regulation of peripheral vascular tone in obesity and diabetes, but they argue against a specific effect of endothelin in diabetes- and obesity-associated blood pressure elevations.",
keywords = "blood pressure, diabetes, Endothelin, insulin resistance, obesity",
author = "Nancy Yoon and Amale Lteif and KyungAh Han and Kieren Mather",
year = "2008",
month = "5",
doi = "10.1016/j.jash.2007.10.006",
language = "English",
volume = "2",
pages = "182--191",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes

AU - Yoon, Nancy

AU - Lteif, Amale

AU - Han, KyungAh

AU - Mather, Kieren

PY - 2008/5

Y1 - 2008/5

N2 - Endothelin contributes to abnormalities in peripheral blood vessel function of subjects with obesity, with or without concurrent type 2 diabetes mellitus, but it is unknown if endothelin contributes specifically to obesity and diabetes-associated changes in blood pressure. We evaluated the effect of systemic endothelin antagonism on peripheral and central hemodynamics and peripheral vascular tone in lean, obese, and type 2 diabetic subjects without overt hypertension by cuff plethysmography. We measured the effects of acute systemic infusions of BQ123 (an antagonist of type A endothelin receptors) in seven lean (body mass index [BMI] 22.7 ± 3.2 kg/m2), seven obese (BMI 35.8 ± 4.6), and six diabetic subjects (BMI 38.2 ± 5.0, glycosylated hemoglobin 8.1 ± 2.2%). BQ123 was infused via antecubital vein sequentially at infusion rates from 0.1 to 1.0 μmol/min. Diastolic blood pressure was significantly lower than baseline across this dose range, but without a clear dose dependence and without differences in the dose response across groups. Obese and diabetic subjects exhibited progressive dilation of peripheral blood vessels (P ≤ .01), with 0.03 and 1.0 μmol/min BQ123 (P = .03 comparing integrated response across groups). No significant changes were observed in systolic blood pressure, cardiac index, or stroke index. These observations confirm the relevance of endothelin in the abnormal regulation of peripheral vascular tone in obesity and diabetes, but they argue against a specific effect of endothelin in diabetes- and obesity-associated blood pressure elevations.

AB - Endothelin contributes to abnormalities in peripheral blood vessel function of subjects with obesity, with or without concurrent type 2 diabetes mellitus, but it is unknown if endothelin contributes specifically to obesity and diabetes-associated changes in blood pressure. We evaluated the effect of systemic endothelin antagonism on peripheral and central hemodynamics and peripheral vascular tone in lean, obese, and type 2 diabetic subjects without overt hypertension by cuff plethysmography. We measured the effects of acute systemic infusions of BQ123 (an antagonist of type A endothelin receptors) in seven lean (body mass index [BMI] 22.7 ± 3.2 kg/m2), seven obese (BMI 35.8 ± 4.6), and six diabetic subjects (BMI 38.2 ± 5.0, glycosylated hemoglobin 8.1 ± 2.2%). BQ123 was infused via antecubital vein sequentially at infusion rates from 0.1 to 1.0 μmol/min. Diastolic blood pressure was significantly lower than baseline across this dose range, but without a clear dose dependence and without differences in the dose response across groups. Obese and diabetic subjects exhibited progressive dilation of peripheral blood vessels (P ≤ .01), with 0.03 and 1.0 μmol/min BQ123 (P = .03 comparing integrated response across groups). No significant changes were observed in systolic blood pressure, cardiac index, or stroke index. These observations confirm the relevance of endothelin in the abnormal regulation of peripheral vascular tone in obesity and diabetes, but they argue against a specific effect of endothelin in diabetes- and obesity-associated blood pressure elevations.

KW - blood pressure

KW - diabetes

KW - Endothelin

KW - insulin resistance

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=43949120777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949120777&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2007.10.006

DO - 10.1016/j.jash.2007.10.006

M3 - Article

C2 - 20409901

AN - SCOPUS:43949120777

VL - 2

SP - 182

EP - 191

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 3

ER -